Dr. Meng-Yin YANGTaiwan
Taichung Veterans General Hospital
to present | Director of Neurosurgical Oncology, Neurology Medical Center, Taichung Veterans General Hospital |
to present | Deputy Director of Cell Therapy and Regenerative Medicine Center, Taichung Veterans General Hospital |
to present | Vice Secretary-General and Chairperson of the International Medical Committee of the Taiwan Neurosurgical Society. Secretary-General of the Taiwan Neurosurgical Spine Society |
- | National Defense Medical Center, Taipei, Taiwan, M.D. degree |
- | Clinical and research fellow, Department of Surgery/Neurosurgery, David Geffen School of Medicine at UCLA, LA, United States |
- | Doctor of Philosophy, Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan |
Neurosurgery (brain surgery, spine surgery, immunotherapy for brain tumor, cell therapy)
High expression of L-VEGF144 in glioblastoma multiforme and its impact on bevacizumab treatment outcomes
1108 16:10-16:20
Neuro-oncology/305
Abstract
Introduction Apreviousstudyconfirmedthatanovelsplicingvariantoflargevascularendothelialgrowthfactor(L-VEGF) termed L-VEGF144, a nucleolus protein, is found in glioblastoma cells and specimens, but the actual biological function and clinical significance of L-VEGF144 remain unclear.
Methods In this study, we analyzed the expression of L-VEGF144 in 68 glioblastoma multiforme specimens using reverse transcriptase-polymerase chain reaction analysis.
Results The results showed that the high expression of L-VEGF144 was associated with a poor prognosis in the bevaci- zumab plus concurrent chemoradiotherapy with temozolomide treatment. In addition, we constructed a series truncated and mutant form of L-VEGF144 to confirm that exon 6a of L-VEGF144 is able to engage in the nuclear importation and found that 8 lysines within exon 6a play a critical role in the nucleolus aggregation of L-VEGF144. Also, the transfection of the L-VEGF144 increased the number of nucleoli. Furthermore, the recombinant protein Flag-L-VEGF144 and commercial VEGF protein have similar growth stimulatory activities in terms of inducing glioblastoma cell proliferation in vitro. Conclusions Taken together, these results indicated that the expression of L-VEGF144 could potentially serve as an inde- pendent indicator of poor prognosis in bevacizumab treatment.
Keywords Bevacizumab · Nucleolus protein · Novel VEGF isoform · GBM Prognosis · Mitogen